Narrative as Strategy: Why Pharma Leaders Must Speak -By Patrick Iwelunmor

There is a defining shift taking place in the pharmaceutical sector, one that is no longer driven solely by research pipelines, regulatory approvals or quarterly returns, but by something less tangible and far more consequential: narrative. For generations, pharmaceutical success was measured by production volumes, distribution reach, compliance records and profitability. These remain important, of course. Yet in the 21st century, influence increasingly depends on how companies and their leaders are perceived by policymakers, regulators, professional peers, investors and the public. In this context, silence is no longer neutral; it is consequential, and leaders too often find themselves defined by stories they neither authored nor shaped.

The COVID-19 pandemic made this shift unmistakably plain. It was not only health systems that were tested; credibility itself came under scrutiny. Institutions that lacked clear, consistent communication found themselves not just managing disease but managing distrust. For pharmaceutical executives, this represents a pivotal inflection point. Leadership can no longer remain purely operational. It must also be interpretive, capable of explaining complex realities, guiding public understanding and asserting clarity during crises. Yet across the sector, a persistent gap endures. Important work is being done, but it is too often insufficiently articulated, leaving its broader significance underappreciated.

This gap between action and narrative is not abstract. It plays out in brands that have become part of everyday life because they are accompanied by stories that resonate across generations. May & Baker Nigeria Plc, the country’s first indigenous pharmaceutical manufacturer, offers a prime example. Founded in 1944, May & Baker’s products have accompanied families for decades. Essentials such as M&B Paracetamol or M&B Cough Syrup evoke vivid memories for many: the relief of a childhood fever, the familiar bottle in a home cabinet, the trusted name on a medicine label. These products have transcended commercial utility to become shared cultural touchstones, illustrating how trust, familiarity and lived experience can reinforce both brand equity and market relevance.

That trust is not accidental. It has emerged over time through consistency of product quality, reliability of supply and a quiet relationship with ordinary lives. May & Baker’s continued growth and operational resilience in recent years demonstrate that equity built through lived experience translates into tangible market value. According to industry reports, Nigeria imports over 70 per cent of its active pharmaceutical ingredients, highlighting the strategic importance of local manufacturers in building resilience, confidence and credibility. Therefore, the transgenerational impact of May & Baker on families is a huge narrative in itself, one that remains unobliterated from cultural memory.

Similarly, Dr Stella Chinyelu Okoli, founder of Emzor Pharmaceutical Industries, exemplifies how executive vision can align with national imperatives. From a modest retail chemist in Lagos in 1977, Emzor has grown into one of Nigeria’s leading indigenous drug manufacturers, producing more than 140 products and exporting to over 25 countries. Under Dr Okoli’s leadership, Emzor is investing approximately $23 million in an Active Pharmaceutical Ingredient production facility in Sagamu, Ogun State. The facility aims to reduce Nigeria’s dependence on imported APIs, strengthen medicine security and address structural vulnerabilities highlighted by global supply chain shocks. The impact of such initiatives is magnified when corporate action is framed within national health priorities, linking enterprise success to public good. Dr. Okoli’s towering vision typifies a robust narrative, embellished with promise, purpose and pride.

Globally, pharmaceutical leaders increasingly recognise the importance of narrative. In the UK and Europe, executives have leveraged thought leadership to shape public discourse on drug safety, innovation and access, gaining influence over policy and public perception. Nigerian industry leaders who communicate consistently and strategically can achieve similar impact, not only strengthening domestic credibility but also positioning local firms as global players capable of shaping international conversations.

Communication as strategy is particularly urgent in addressing the country’s health workforce challenges. Nigeria currently has fewer than four physicians per 10,000 people, far below the WHO-recommended minimum of ten. Thousands of health professionals have migrated abroad, representing both a loss of critical expertise and a flight of public investment. How leaders frame these issues, whether defensively, passively or proactively, affects policy reception, stakeholder trust and sector influence. The same principle applies to pricing debates, regulatory tensions and supply chain disruptions, where silence can create space for speculation and erode confidence.

Pharmaceutical executives must articulate purpose consistently by linking corporate initiatives to national health objectives and public wellbeing. They need to engage proactively in policy discourse, contributing insights to regulatory and professional forums. Leveraging multiple channels, including media, industry publications and digital platforms, ensures messages reach domestic and international audiences. Investing in narrative-driven leadership ensures communications reflect operational reality, technical expertise and societal impact. Leaders who build credibility over time, rather than reacting only in moments of crisis, secure influence in a sector that depends as much on trust as on innovation.

Evidence suggests that companies with strong executive narratives enjoy measurable advantages. Firms that communicate effectively are better positioned to attract talent, influence policy and gain investor confidence. In Nigeria, this means positioning local pharmaceutical leaders not just as operational managers, but as trusted voices in health innovation, industrial policy and public discourse.

Ultimately, the pharmaceutical industry runs on trust: trust in products, trust in processes and trust in leadership. In an era of rapid information flows and heightened scrutiny, trust is no longer assumed; it must be earned and actively communicated. Nigerian pharma leaders who recognise this shift and embrace narrative as a strategic tool stand to redefine the sector’s influence domestically and internationally.

Looking forward, the next competitive advantage in Nigeria’s pharmaceutical industry will not be built on products alone, but on narrative. Leaders must ensure that what is done is effective, understood, appreciated and enduringly credible. In doing so, Nigerian pharmaceutical executives can not only strengthen their companies but also contribute meaningfully to national development and global health discourse, shaping the sector’s future with authority and vision.